Developmental Schizotypy In The General Population: Early Risk Factors And Predictive Utility.
Funder
National Health and Medical Research Council
Funding Amount
$830,952.00
Summary
This study will determine early childhood risk factors for psychosis-proneness in children aged 11 years, and emerging signs and symptoms of mental health disorders of these children, using population data from the NSW Child Development Study. Determining risk for psychosis as early as possible in the life course will enable the provision of preventative interventions to children at critical points in development.
Improving Global Tuberculosis Control With The AuTuMN Platform
Funder
National Health and Medical Research Council
Funding Amount
$655,059.00
Summary
Tuberculosis (TB) is the world’s leading infectious killer, with the failure of global control responsible for the vast majority of Australia’s cases. Using our robustly developed software platform, we have performed several country-level studies to predict the future burden of disease and compare the impact of alternative responses to controlling the epidemic. In this project, we will extend our platform to perform simulations at the global level and answer key questions in TB control.
Probiotic Prawn Oral Immunotherapy (ProPIT) For Treatment Of Prawn Allergy
Funder
National Health and Medical Research Council
Funding Amount
$1,865,369.00
Summary
A ‘curative’ food allergy treatment is needed to prevent deaths and improve care. We recently showed that probiotic peanut oral immunotherapy (PPOIT) was highly effective for treating peanut allergy. 82% of PPOIT treated children gained tolerance compared to 4% of the placebo group. We will now test the combined probiotic-food OIT approach for treating prawn allergy. If successful, we will have identified the first treatment for prawn allergy and a platform treatment for other food allergies.
Group A Streptococcal Human Challenge Study: Accelerating Vaccine Development
Funder
National Health and Medical Research Council
Funding Amount
$2,018,741.00
Summary
Infection with group A streptococcus (GAS) is a major cause of morbidity and mortality worldwide, including in the Aboriginal population of Australia. Concerted efforts for vaccine development have been hampered by the absence of a suitable animal model. To address this critical knowledge gap we propose to develop a controlled human infection model of GAS infection. This model will provide a direct pathway for the future appraisal of novel GAS vaccines.
N-Acetyl Cysteine In Schizophrenia Resistant To Clozapine: A Double-Blind Randomised Placebo-Controlled Trial Targeting Negative Symptoms
Funder
National Health and Medical Research Council
Funding Amount
$981,789.00
Summary
Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.
A Randomised Controlled Trial Of Interventional Versus Conservative Treatment Of Primary Spontaneous Pneumothorax
Funder
National Health and Medical Research Council
Funding Amount
$412,315.00
Summary
Primary spontaneous pneumothorax (PSP) is a collapsed lung that occurs in otherwise healthy people without underlying lung disease. Current standard treatment is to insert a chest drain into the chest to remove the air around the collapsed lung so that the lung re-inflates rapidly ("interventional treatment"). We will determine whether doing nothing, i.e. letting the lung re-inflate slowly on its own over several weeks ("conservative treatment"), is just as good or even better for patients.
Which Heart Failure Intervention Is Most Cost Effective In Reducing Hospital Care (WHICH? II) Trial: A Multicentre, Randomised Trial Of Standard Versus Intensified Management Of Metropolitan And Regional-dwelling Patients With Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$1,891,210.00
Summary
Chronic heart failure (CHF) management programs are now the gold-standard to cost-effectively care for thousands of Australians hospitalised with CHF each year. We’ve shown that home-based management is most cost-effective in reducing hospital stay in CHF. The Which Intervention is most Cost-effective in reducing Hospital care (WHICH? II) Trial, a multicentre, randomised study, will determine if more intensive care (via home visits and remote care contacts) further improves poor outcomes in CHF.
Re-EValuating The Inhibition Of Stress Erosions (REVISE): Gastrointestinal Bleeding Prophylaxis In ICU
Funder
National Health and Medical Research Council
Funding Amount
$2,955,164.00
Summary
Around 50,000 patients in Australian Intensive Care Units receive a drug called pantoprazole each year with the aim of preventing bleeding from the gut. Recent research suggests this practice is ineffective and may harm patients by increasing their risk of serious infections. We will perform a definitive study to determine whether the widespread use of pantoprazole is beneficial or harmful.
A Phase III Trial Comparing Adjuvant Versus Salvage Radiotherapy For High Risk Patients Post Radical Prostatectomy
Funder
National Health and Medical Research Council
Funding Amount
$819,138.00
Summary
About half of all patients Treated with an operation to remove their prostate cancer have a high chance of the cancer coming back. Giving immediate radiotherapy to all patients will improve cure rates but does not benefit all men and can cause significant side effects. This study explores whether it is safe to wait and only give radiotherapy when there is a rising PSA after surgery indicating active cancer. A total of 470 men from Australasia will enter this study comparing the two approaches.